Targeting Tumor Necrosis Factor Alpha for Alzheimer’s Disease

Author(s): Boris Decourt, Debomoy K. Lahiri, Marwan N. Sabbagh

Journal Name: Current Alzheimer Research

Volume 14 , Issue 4 , 2017

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor


Alzheimer’s disease (AD) affects an estimated 44 million individuals worldwide, yet no therapeutic intervention is available to stop the progression of the dementia. Neuropathological hallmarks of AD are extracellular deposits of amyloid beta (Aβ) peptides assembled in plaques, intraneuronal accumulation of hyperphosphorylated tau protein forming tangles, and chronic inflammation. A pivotal molecule in inflammation is the pro-inflammatory cytokine TNF-α. Several lines of evidence using genetic and pharmacological manipulations indicate that TNF-α signaling exacerbates both Aβ and tau pathologies in vivo. Interestingly, preventive and intervention anti-inflammatory strategies demonstrated a reduction in brain pathology and an amelioration of cognitive function in rodent models of AD. Phase I and IIa clinical trials suggest that TNF-α inhibitors might slow down cognitive decline and improve daily activities in AD patients. In the present review, we summarize the evidence pointing towards a beneficial role of anti-TNF-α therapies to prevent or slow the progression of AD. We also present possible physical and pharmacological interventions to modulate TNF-α signaling in AD subjects along with their limitations.

Keywords: Alzheimer’s disease, BACE1, etanercept, inflammation, neuroinflammation, thalidomide, TNF-α.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Published on: 16 February, 2017
Page: [412 - 425]
Pages: 14
DOI: 10.2174/1567205013666160930110551
Price: $65

Article Metrics

PDF: 84
HTML: 18